Economic information and modeling reportBudget impact model
Cost assumptions
9 evidence topics · 8 sources
ICER potential budget impact analysis: prices evaluated
ICER cost-effectiveness models: dosing regimens costed for tavapadon and comparators
| Intervention | Quoted dosing | Quoted annual drug cost |
|---|---|---|
| Tavapadon | “5–15 mg once daily” | “$15,000 (placeholder)” |
| Levodopa (Model 1) | “Carbidopa/levodopa 25/100 mg, 8×/day” | “$289” |
| Dopamine agonist market basket (Model 2) | “Ropinirole 3 mg TID; pramipexole 1 mg TID; rotigotine 2 mg/24-hr patch” | “$3,588 (weighted)” |
| Monotherapy market basket (Model 2) | “65% Carbidopa/levodopa 25/100 mg, 8×/day; 35% on DA market basket (Ropinirole 3 mg TID; pramipexole 1 mg TID; rotigotine 2 mg/24-hr patch)” | “$1,444” |